Immunocore Holdings plc (NASDAQ:IMCR) Shares Sold by Cwm LLC

Cwm LLC lessened its stake in Immunocore Holdings plc (NASDAQ:IMCR) by 54.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 24,225 shares of the company’s stock after selling 29,176 shares during the period. Cwm LLC’s holdings in Immunocore were worth $1,655,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. RTW Investments LP grew its position in Immunocore by 1.1% in the 3rd quarter. RTW Investments LP now owns 6,096,387 shares of the company’s stock valued at $316,402,000 after acquiring an additional 66,754 shares in the last quarter. Wellington Management Group LLP increased its stake in Immunocore by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,913,410 shares of the company’s stock worth $203,106,000 after buying an additional 217,920 shares during the period. FMR LLC lifted its holdings in Immunocore by 4.4% during the 3rd quarter. FMR LLC now owns 2,136,223 shares of the company’s stock worth $110,870,000 after buying an additional 90,116 shares in the last quarter. Braidwell LP raised its stake in shares of Immunocore by 93.8% in the third quarter. Braidwell LP now owns 906,973 shares of the company’s stock valued at $47,072,000 after acquiring an additional 438,946 shares in the last quarter. Finally, Fiera Capital Corp boosted its stake in shares of Immunocore by 30.4% in the 3rd quarter. Fiera Capital Corp now owns 679,799 shares of the company’s stock valued at $35,282,000 after buying an additional 158,502 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Wall Street Analyst Weigh In

IMCR has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Immunocore in a research report on Wednesday, March 6th. JPMorgan Chase & Co. raised their price target on Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Needham & Company LLC reiterated a “buy” rating and issued a $81.00 price objective on shares of Immunocore in a research note on Thursday, April 11th. Canaccord Genuity Group lifted their price objective on shares of Immunocore from $60.00 to $63.00 and gave the company a “hold” rating in a research note on Thursday, February 29th. Finally, Guggenheim restated a “buy” rating and set a $92.00 price target on shares of Immunocore in a research note on Tuesday. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.50.

Immunocore Stock Performance

NASDAQ:IMCR opened at $58.46 on Friday. The firm’s fifty day simple moving average is $62.34 and its 200-day simple moving average is $60.65. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13. The stock has a market cap of $2.91 billion, a PE ratio of -50.40 and a beta of 0.89. Immunocore Holdings plc has a fifty-two week low of $42.21 and a fifty-two week high of $76.98.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.12). Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The company had revenue of $70.16 million for the quarter, compared to analysts’ expectations of $53.25 million. During the same period in the prior year, the firm posted ($0.63) EPS. The firm’s quarterly revenue was up 22.4% on a year-over-year basis. Analysts expect that Immunocore Holdings plc will post -1.54 earnings per share for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.